Ketamine Shows Significant Therapeutic Benefit in People with Treatment-Resistant Depression
Patients with treatment-resistant major depression saw dramatic improvement in their illness after treatment with ketamine, an anesthetic, according to the largest ketamine clinical trial to-date led by researchers from the Icahn School of Medicine at Mount Sinai. The antidepressant benefits of ketamine were seen within 24 hours, whereas traditional antidepressants can take days or weeks to demonstrate a reduction in depression. Led by Dan Iosifescu, MD, Associate Professor of Psychiatry at Mount Sinai; Sanjay Mathew, MD, Associate Professor of Psychiatry at Baylor College of Medicine; and James Murrough, MD Assistant Professor of Psychiatry at Mount Sinai, the research team evaluated 72 people with treatment-resistant depression—meaning their depression has failed to respond to two or more medications—who were administered a single intravenous infusion of ketamine for 40 minutes or an active placebo of midazolam, another type of anesthetic without antidepressant properties.
-Dr. Dan V. Iosifescu, Associate Professor, Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai
-Dr. James Murrough, Assistant Professor, Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai
Learn more
Mechanism by Which the Brain Weighs Positive vs. Negative Social Experience Is Revealed
Apr 30, 2025 View All Press Releases
